Graves' Ophthalmopathy Treatments — CPB 0419 | AETNA Coverage Update

Aetna modified CPB 0419 for Graves' ophthalmopathy treatments, effective September 26, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated CPB 0419 — its coverage policy governing surgical and medical treatments for Graves' ophthalmopathy. This policy affects more than 60 CPT and HCPCS codes, including orbital decompression procedures (CPT 61330, 67414, 67445), strabismus surgery codes (CPT 67311–67343), blepharoplasty (CPT 15820–15823), and several injectable biologics and immune globulins. If your practice bills for oculoplastic, orbital, or ophthalmic procedures under Aetna commercial plans, this update applies to your claims starting September 26, 2025.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna (Commercial)
Policy	Graves' Ophthalmopathy Treatments
Policy Code	CPB 0419
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	High
Specialties Affected	Ophthalmology, Oculoplastics, Orbital Surgery, Endocrinology, Infusion Therapy
Key Action	Audit charge capture for all CPT 67311–67343, 61330, 67414, 67445, and associated HCPCS drug codes before billing under Aetna commercial plans

---

Aetna Graves' Ophthalmopathy Coverage Criteria and Medical Necessity Requirements 2025

CPB 0419 is the Aetna coverage policy for Graves' ophthalmopathy — also called thyroid eye disease — a condition that causes orbital inflammation, proptosis, lid retraction, strabismus, and compressive optic neuropathy in patients with thyroid dysfunction. This policy governs which surgical procedures and medical treatments Aetna considers medically necessary versus experimental for its commercial members.

The policy applies to commercial medical plans only. For Medicare Advantage members, Aetna directs you to its Medicare Part B criteria — a separate set of rules. Don't assume these commercial criteria apply to your Medicare Advantage population.

Aetna covers surgical interventions when selection criteria are met. That phrase — "when selection criteria are met" — is doing a lot of work here. It means prior authorization is required for the covered codes, and medical necessity documentation must support each claim. Your clinical notes need to reflect the severity of the condition and the specific indication driving surgery.

The covered procedures fall into clear clinical categories. Orbital decompression (CPT 61330, 67414, 67445) addresses proptosis and optic nerve compression. Strabismus surgery (CPT 67311 through 67343) corrects diplopia caused by extraocular muscle involvement. Blepharoplasty (CPT 15820, 15822) and ptosis repair (CPT 67901–67908) address lid malposition. Lid retraction correction (CPT 67911) and canthoplasty (CPT 67950) round out the oculoplastic interventions. Radiation therapy via surface brachytherapy (CPT 77789) also falls under covered services when criteria are met.

Reimbursement for these procedures depends entirely on documentation matching Aetna's selection criteria. A claim for CPT 67414 without supporting documentation of compressive optic neuropathy or severe proptosis is a claim denial waiting to happen.

Immune globulin administration — including IV infusion codes like CPT 90283 and HCPCS J1459, J1561, J1566, J1568, J1569, J1572 — appears in the policy as a treatment modality. Infusion-related chemotherapy administration codes CPT 96413 and 96415 are also listed as related codes. These suggest coverage exists for IV methylprednisolone or similar infusion protocols, again conditional on medical necessity criteria.

Somatostatin analogs lanreotide (HCPCS J1930, J1932) and octreotide (HCPCS J2353) appear in the HCPCS section. These drugs are sometimes used in active Graves' ophthalmopathy management. Their placement in the policy signals Aetna has considered their use in this clinical context — but their coverage group label ("no specific code") means documentation and prior authorization requirements are critical before billing.

---

Aetna Graves' Ophthalmopathy Exclusions and Non-Covered Indications

Several treatments fall into a "no specific code" designation in CPB 0419. This isn't a billing technicality — it reflects Aetna's position that these therapies lack sufficient clinical evidence for routine coverage.

T-helper (Th) 17 cell therapy is grouped with CPT 15821, 15823, 90281, 90283, and 90284. The "no specific code" label signals that Aetna does not recognize a distinct billing pathway for this emerging treatment. If you're treating patients with Th17-directed therapies, expect coverage challenges.

Celecoxib, gypenosides, and pioglitazone are grouped with most of the HCPCS drug codes, including biologics like adalimumab (J0135, J0139), etanercept (J1438), certolizumab pegol (J0717), infliximab (J1745), and brachytherapy sources (C2698, C2699). The "no specific code" grouping suggests Aetna views these agents as investigational for Graves' ophthalmopathy specifically, even when they're covered for other indications.

The real risk here: your provider may be using adalimumab or infliximab off-label for a patient with severe thyroid eye disease. The biologic HCPCS codes exist in this policy, but their coverage designation puts them in experimental territory for this specific diagnosis. That's a claim denial risk your billing team and medical director need to discuss before submitting.

---

Coverage Indications at a Glance

---

Aetna Graves' Ophthalmopathy Billing Guidelines and Action Items 2025

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Graves' Ophthalmopathy Under CPB 0419

Covered CPT Codes (When Selection Criteria Are Met)

Other CPT Codes Related to CPB 0419

Code	Type	Description Copy
96413	CPT	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance
96415	CPT	Chemotherapy administration, intravenous infusion technique; each additional hour

CPT Codes Flagged — No Specific Code (Th17 Cell Therapy / Investigational)

HCPCS Codes — No Specific Code (Celecoxib, Gypenosides, Pioglitazone, Biologics)

Key ICD-10-CM Diagnosis Codes

The policy data for CPB 0419 does not list specific ICD-10-CM codes. Your team should use the appropriate thyroid eye disease and Graves' ophthalmopathy diagnosis codes from your encoder — but Aetna has not enumerated them in this bulletin. Confirm coding with your billing guidelines documentation and encoder before submitting claims.

---